UPDATED: Hedge fund aims to oust Depomed board for ‘troubling record’

Eric Palmer If Depomed thought it was free to chart its own course after foiling a takeover by Horizon Pharma last year, it can think again. A hedge fund practiced in the art of board ...

Top 10 mega-rounds fuel record VC pace, with a distinctly ex-U.S. biotech accent

John Carroll FierceBiotech News

AbbVie hands United a record $350M payoff for a speedy FDA review voucher

John Carroll The cost of a priority review voucher for the FDA keeps going up. AbbVie is forking over a record $ 350 million to acquire a voucher from United Therapeutics, giving them ...

Pharma wanted pricey orphan meds, and now it’s got ’em in record numbers

Carly Helfand New drug approvals were up last year, and orphan drug approvals were no exception. But by just how much did they climb? The FDA Law Blog has done some digging ...

Pfizer’s post-megamerger cost-cutting record? 51,500 jobs in 7 years

Tracy Staton In the calm after yesterday's Pfizer-AstraZeneca deal storm, it's time to survey the potential fallout. Pfizer's aggressive strategy for avoiding taxes, totted ...

FDA’s 2013 approvals record falls short of 2012 pace

Tracy Staton The good news: The FDA approved 18 new drugs during the first 8 months of this year. The not-so-good news: Last year, during the same time frame, the agency blessed 22 ...

FDA’s Hamburg touts rising approval record and promises swifter interaction

John Carroll Margaret Hamburg, the head of the FDA, turned up at Reuters Health Summit with a bullish assessment of both the agency's responsiveness as well as the biopharma industry's ...
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS